| Literature DB >> 29017052 |
W Nathaniel Brennen1, John T Isaacs2.
Abstract
In this issue of Cancer Cell, Bluemn et al. report that ∼20% of metastatic castration-resistant prostate cancers express neither AR nor neuroendocrine genes and show AR pathway-independent growth, driven instead by a FGFR/MAPK/ID1 signaling cascade. These results provide a strong rationale for co-targeting AR bypass pathways with initial AR antagonism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29017052 DOI: 10.1016/j.ccell.2017.09.011
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743